SGMO
Sangamo BioSciences, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, Dec. 1, 11:28 AM
    • Sangamo BioSciences (SGMO) appoints Edward Connor, M.D. as SVP and chief medical officer effective immediately. He joins the firm from Ultragenyx Pharmaceutical (RARE -1.4%).
    • VP of corporate development Curt Herberts has been promoted to the newly created role of SVP and chief business officer. He joined the company in October 2010.
    | Thu, Dec. 1, 11:28 AM
  • Fri, Nov. 4, 8:16 AM
    • Almost Family (NASDAQ:AFAM) upgraded to Outperform from Neutral by Baird. Price target raised to $55 (35% upside) from $44.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Outperform from Market Perform by BMO Capital. Price target lowered to $84 (17% upside) from $98.
    • Dentsply Sirona (NASDAQ:XRAY) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $69 (16% upside) from $65.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Strong Buy from Buy by Needham. Price target lowered to $148 (44% upside) from $150.
    • Stryker (NYSE:SYK) upgraded to Market Perform from Underperform with a $125 (8% upside) price target by BMO Capital.
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Neutral by Credit Suisse. Price target lowered to $52 (33% upside) from $59.
    • Cempra (NASDAQ:CEMP) downgraded to Hold from Buy by Stifel Nicolaus. Price target lowered to $8 (6% upside) from $37. Downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $6 (21% downside risk) from $25. Downgraded to Underperform from Outperform by Baird. Price target lowered to $6 (21% downside risk) from $33.
    • Diplomat Pharmacy (NYSE:DPLO) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $18 (39% upside) from $35. Downgraded to Market Perform by Citigroup and Avondale Partners.
    • WebMD (NASDAQ:WBMD) downgraded to Neutral from Buy by Mizuho Securities. Price target lowered to $52 (5% upside) from $63.
    • Pfizer (NYSE:PFE) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $33 (10% upside) from $40. Downgraded to Hold from Buy by Argus.
    • Adeptus Health (NYSE:ADPT) downgraded to Underperform from Buy by Bank of America. Downgraded to Hold from Buy by Jefferies. Price target lowered to $13 (48% upside) from $77.
    • Sangamo BioSciences (NASDAQ:SGMO) downgraded to Neutral from Overweight by Wedbush and Piper Jaffray. Price targets lowered to $4 (25% upside) from $30 and $5 (56% upside) from $9, respectively.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Buy by Citigroup and to Hold from Buy by DNB Markets.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $60 (7% upside) from $70.
    | Fri, Nov. 4, 8:16 AM | 18 Comments
  • Mon, Oct. 31, 11:36 AM
    • Shire plc (SHPG -3.3%) slumps in early trading on increased volume in apparent response to comments made by Express Scripts (ESRX +2.6%) Chief Medical Officer Steven Miller during a phone interview. He said the company is mulling ways to manage the rising costs of hemophilia medicines without forcing patients to switch treatments. Shire is a major player in the space after its merger with Baxalta. Hemophilia products accounted for over 46% of Baxalta's business in 2015.
    • Related tickers: (OTCPK:BAYRY -0.7%)(PFE -0.2%)(NVO -0.4%)(BMRN -0.6%)(BAX +0.9%)(BIIB -0.4%)(SGMO +1.4%)
    | Mon, Oct. 31, 11:36 AM | 3 Comments
  • Wed, Oct. 26, 4:19 PM
    • Sangamo BioSciences (NASDAQ:SGMO): Q3 EPS of -$0.27 misses by $0.02.
    • Revenue of $2.8M (-67.3% Y/Y) misses by $1.44M.
    • Press Release
    | Wed, Oct. 26, 4:19 PM | 4 Comments
  • Tue, Oct. 25, 5:35 PM
  • Tue, Oct. 25, 9:58 AM
    • See J.P.Morgan note here
    • JPM has a $13 price target on SGMO (vs. current $3.85).
    • Says SGMO's hemophilia therapy may be more potent than BioMarin and Spark's.
    | Tue, Oct. 25, 9:58 AM
  • Wed, Oct. 19, 11:00 AM
    | Wed, Oct. 19, 11:00 AM | 3 Comments
  • Tue, Oct. 18, 6:51 PM
    • Sangamo BioSciences (NASDAQ:SGMO) EVP, R&D Geoffrey Nichol, M.B., Ch.B., has notified the company that he will resign effective October 25. No word is provided on the company's plan for a successor or the reasons for his departure.
    | Tue, Oct. 18, 6:51 PM | 2 Comments
  • Thu, Sep. 29, 10:39 AM
    • The Japanese Ministry of Health, Labor and Welfare approves CSL Behring's IDELVION (Albutrepenonacog Alfa) for the prevention of bleeding tendency in patients with hemophilia B (factor IX deficiency). The specific approval includes routine prophylaxis, on-demand control of bleeding episodes and the perioperative management of bleeding.
    • IDELVION maintains factor IX activity at an average of 20% when administered prophylactically every seven days and at an average of 12% when administered every 14 days.
    • Hemophilia B-related tickers: (NASDAQ:QURE)(NASDAQ:ONCE)(NYSE:NVO)(NYSE:BAX)(NASDAQ:BIIB)(NASDAQ:DMTX)(NASDAQ:SGMO)
    | Thu, Sep. 29, 10:39 AM
  • Tue, Sep. 6, 7:11 AM
    • Sangamo BioSciences(NASDAQ:SGMO) announces that the FDA has granted orphan drug designation to SB-FIX, the company's zinc finger nuclease ("ZFN")-mediated genome editing product candidate for the treatment of hemophilia B.
    • Sangamo expects to initiate a Phase 1/2 clinical study (SB-FIX-1501) in adult subjects with the disease in 2016.
    • Management commentt: "By enabling targeted integration of a therapeutic factor 9 gene, our ZFN-mediated genome editing approach may offer hemophilia B patients a therapeutic option that has potential advantages over conventional gene therapy approaches. We will enroll adult hemophilia patients into our first clinical trial, however, our goal is to move into pediatric patients, a population we believe could particularly benefit from a treatment that has the potential to provide lifelong expression of therapeutic levels of Factor IX protein."
    • Source: Press Release
    | Tue, Sep. 6, 7:11 AM | 2 Comments
  • Thu, Aug. 4, 12:55 PM
    | Thu, Aug. 4, 12:55 PM | 1 Comment
  • Thu, Aug. 4, 11:00 AM
    | Thu, Aug. 4, 11:00 AM | 1 Comment
  • Thu, Aug. 4, 9:16 AM
    | Thu, Aug. 4, 9:16 AM | 2 Comments
  • Wed, Aug. 3, 7:06 PM
    • After a healthy climb over the past two weeks (of more than 25%), Sangamo BioSciences (NASDAQ:SGMO) has dropped 21.9% and falling after hours in the wake of a Q2 earnings report featuring a net loss that doubled Y/Y and revenues that fell off to $3.7M.
    • The bulk of those sales came from collaboration agreements that Sangamo has with Biogen and Shire; the drop of 55.7% is largely due to amending its Shire deal last Q3, which returned rights to hemophilia programs to Sangamo.
    • The company's in transition from a research-focused organization to a clinical-stage product development company "capable of building a versatile portfolio of therapeutics based on both our proprietary zinc finger nuclease and gene therapy platforms," says CEO Sandy Macrae, who joined this summer from Takeda Pharmaceuticals.
    • Research and development expense came to $19.5M vs. a year-ago $15.6M. Total operating expenses had grown nearly 50%, to $30.5M.
    • Sangamo has cash, equivalents, marketable securities and interest receivable of $172.6M.
    • Press Release
    | Wed, Aug. 3, 7:06 PM | 2 Comments
  • Wed, Aug. 3, 5:35 PM
    | Wed, Aug. 3, 5:35 PM
  • Wed, Aug. 3, 4:14 PM
    • Sangamo BioSciences (NASDAQ:SGMO): Q2 EPS of -$0.38 misses by $0.14.
    • Revenue of $3.7M (-55.7% Y/Y) misses by $1.68M.
    • Press Release
    | Wed, Aug. 3, 4:14 PM